Screening for pharmacologic inhibitors of amyloid fibril formation.
LeVine
H
H
Department of Neuroscience Therapeutics, Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, Michigan 48105-1047, USA.
Scholten
J D
JD
D000544:Alzheimer Disease / Q000188:drug therapy; D016229:Amyloid beta-Peptides / Q000032:analysis / Q000037:antagonists & inhibitors*; D016477:Artifacts; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D006801:Humans; D046911:Macromolecular Substances; D010446:Peptide Fragments / Q000032:analysis
D016229:Amyloid beta-Peptides; D046911:Macromolecular Substances; D010446:Peptide Fragments; C078592:amyloid beta-protein (1-40)